Sonis, Stephen T.
Funding for this research was provided by:
Galera Therapeutics
Article History
Received: 15 December 2020
Accepted: 24 February 2021
First Online: 13 March 2021
Declarations
:
: N/A.
: N/A.
: N/A.
: Dr. Sonis reports personal fees from Biomodels, LLC, personal fees from Primary Endpoint Solutions, LLC (PES), outside of the submitted work. As an employee of Biomodels and PES, he is involved in assisting industry, government and academics in the study, and enablement of drugs, biologicals, and devices to treat patients for a broad range of indications including cancer and oral toxicities of cancer therapy. He does not have equity or receive payment from any of the companies’ clients. This review was funded in part by a grant to PES from Galera Therapeutics which is among the companies developing a mucositis intervention based on mitigating radiation-induced oxidative stress.